Answers are grounded in this paper and cite their sources.
The development of a vaccine is necessary to combat the global hepatitis C virus (HCV) epidemic. The key to the development of a prophylactic vaccine is understanding the immune response in those who spontaneously resolve HCV infections versus those who develop chronic disease. Several promising vaccine candidates based on the use of viral vectors are currently in Phase I and Phase II clinical trials. The recently solved structures of the E2 glycoprotein have greatly aided epitope- and antibody-based vaccine design.
No takes yet. Share an insight, caveat, or question.
Patel et al. (2015) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: